宣泰医药
(688247)
| 流通市值：13.28亿 | | | 总市值：42.98亿 |
| 流通股本：1.40亿 | | | 总股本：4.53亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 229,422,987.49 | 641,783,808.7 | 141,813,354.62 | 382,114,294.06 |
| 应收票据及应收账款 | 73,499,119.11 | 65,919,444.72 | 42,665,819.27 | 34,360,551.45 |
| 应收账款 | 73,499,119.11 | 65,919,444.72 | 42,665,819.27 | 34,360,551.45 |
| 预付款项 | 26,581,789.79 | 17,856,445.39 | 37,532,147.92 | 27,817,608.26 |
| 其他应收款合计 | 2,572,324.18 | 2,167,143.94 | 2,339,778.36 | 2,046,957.24 |
| 存货 | 80,949,554.54 | 84,609,475.73 | 59,084,195.05 | 68,500,051.53 |
| 合同资产 | 12,582,706.06 | 12,551,220.3 | 11,567,657.23 | 10,052,280.91 |
| 其他流动资产 | 10,842,778.87 | 127,121,199.56 | 12,225,586.03 | 17,212,250.82 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 945,451,260.04 | 952,008,738.34 | 949,228,538.48 | 957,103,994.27 |
| 非流动资产: | | | | |
| 长期股权投资 | 63,629,205.89 | 64,197,542.19 | 68,541,265.85 | 56,537,031.79 |
| 固定资产 | 253,414,557.5 | 255,965,981.09 | 98,119,178.5 | 94,649,255.5 |
| 在建工程 | 16,733,390.72 | 15,354,678.6 | 162,265,961.89 | 162,572,372.56 |
| 使用权资产 | 69,517.31 | 84,413.87 | 99,310.43 | 940,542.73 |
| 无形资产 | 25,865,499.05 | 27,591,084.7 | 27,709,164.56 | 29,246,210.77 |
| 商誉 | 18,385,750.74 | 18,385,750.74 | 18,385,750.74 | 18,385,750.74 |
| 长期待摊费用 | 1,195,755.33 | 1,211,314.47 | 1,380,298.69 | 1,549,282.93 |
| 递延所得税资产 | 15,482,396.53 | 14,285,674.75 | 14,174,025.58 | 15,658,017.76 |
| 其他非流动资产 | 13,061,892.5 | 12,535,073.8 | 13,133,849.97 | 10,635,890 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 407,837,965.57 | 409,611,514.21 | 403,808,806.21 | 390,174,354.78 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,353,289,225.61 | 1,361,620,252.55 | 1,353,037,344.69 | 1,347,278,349.05 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 13,850,247.59 | 14,527,332.94 | 14,244,392.74 | 17,025,637.67 |
| 应付账款 | 13,850,247.59 | 14,527,332.94 | 14,244,392.74 | 17,025,637.67 |
| 合同负债 | 53,319,684.31 | 47,610,636.97 | 66,167,595.59 | 48,397,162.64 |
| 应付职工薪酬 | 8,591,742.24 | 12,755,230.42 | 9,614,568.56 | 8,440,054.95 |
| 应交税费 | 4,546,593.56 | 2,009,999.94 | 378,447.37 | 253,899.06 |
| 其他应付款合计 | 12,812,985.84 | 11,843,899.22 | 10,509,155.19 | 38,747,774.6 |
| 应付股利 | - | - | - | 28,107,080 |
| 一年内到期的非流动负债 | 63,257.19 | 62,671.54 | 61,897.81 | 220,442.56 |
| 其他流动负债 | 1,955,938.27 | 1,907,559.35 | 1,626,396.81 | 2,244,604.34 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 95,140,449 | 90,717,330.38 | 102,602,454.07 | 115,329,575.82 |
| 非流动负债: | | | | |
| 租赁负债 | 6,557.71 | 22,431.78 | 38,482.65 | 746,836.86 |
| 递延收益 | 54,823,883.23 | 58,087,773.53 | 54,523,521.32 | 56,573,159.18 |
| 递延所得税负债 | 2,498,144.53 | 2,533,781.44 | 2,569,418.34 | 2,605,055.25 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 57,328,585.47 | 60,643,986.75 | 57,131,422.31 | 59,925,051.29 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 152,469,034.47 | 151,361,317.13 | 159,733,876.38 | 175,254,627.11 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 453,340,000 | 453,340,000 | 453,340,000 | 453,340,000 |
| 资本公积 | 512,871,036.84 | 512,890,878.87 | 512,890,878.87 | 512,890,878.87 |
| 减:库存股 | 32,314,700.39 | - | - | - |
| 其他综合收益 | -131,399.76 | -131,292.42 | -95,229.49 | -80,923.41 |
| 盈余公积 | 24,565,923.73 | 24,565,923.73 | 22,817,279.21 | 22,817,279.21 |
| 未分配利润 | 242,489,330.72 | 219,593,425.24 | 204,350,539.72 | 183,056,487.27 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,200,820,191.14 | 1,210,258,935.42 | 1,193,303,468.31 | 1,172,023,721.94 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,200,820,191.14 | 1,210,258,935.42 | 1,193,303,468.31 | 1,172,023,721.94 |
| 负债和股东权益合计 | 1,353,289,225.61 | 1,361,620,252.55 | 1,353,037,344.69 | 1,347,278,349.05 |
| 公告日期 | 2024-04-30 | 2024-04-30 | 2023-10-31 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |